MINI FUTURE LONG - ARGENX SE | Real-time Euronext Paris 12:03:51 14/06/2024 BST | ||
| 1.273 EUR | +0.32% |
|
| Current month | +18.05% | ||
| 1 month | +17.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ARGENX SE
Latest news about ARGENX SE
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 1.273 | +0.32% |
| 13/06/24 | 1.269 | +8.65% |
| 12/06/24 | 1.168 | -1.52% |
| 11/06/24 | 1.186 | +0.59% |
| 10/06/24 | 1.179 | -2.56% |
Real-time Euronext Paris
Last update June 14, 2024 at 12:03 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ARGENX SE |
| Issuer | 
BNP Paribas
|
| E65MB | |
| ISIN | NLBNPNL2LQA3 |
| Date issued | 21/12/2023 |
| Strike | 234.7 € |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.512 € |
|---|---|
| Lowest since issue | 0.645 € |
| Spread | 0.005 € |
| Spread % | 0.39% |
Company Profile
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Sector
-
Consensus: argenx SE
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
358.6
EUR
Average target price
436.6
EUR
Spread / Average Target
+21.75%
- Stock Market
- Certificates
- E65MB Certificat